Company: BACC
Filing Date: 2025-05-14
Form Type: S-1
Source: 0001185185-25-000465
Chunk: 11

Company: Blue Acquisition Corp/Cayman
Filing Date: 2025-05-14
Form: S-1
Chunk 11
---
 |
|:---------------------------------------|:----|:---------|------:|:----|:------|------------:|
| Public offering price(1)               |     | $        | 10.00 |     | $     | 150,000,000 |
| Underwriting discounts and commissions |     | $        |  0.55 |     | $     |   8,250,000 |
| Proceeds, before expenses, to us       |     | $        |  9.45 |     | $     | 141,750,000 |

| (1) | Includes $0.20 per unit (including any units sold pursuant to the underwriters’ option to purchase additional units), or $3,000,000 in the aggregate (or $3,450,000 if the underwriters’ over-allotment option is exercised in full), payable to the underwriters upon the closing of this offering. Also includes $0.35 per unit on all units sold including those sold pursuant to the underwriters’ option to purchase additional units, or $5,250,000 in the aggregate (or $6,037,500 in the aggregate if the underwriters’ over-allotment option is exercised in full) payable to the underwriters for deferred underwriting commissions to be deposited into a trust account located in the United States and released to the underwriters for their own account only upon the completion of an initial business combination. The underwriters have received and will receive compensation in addition to the underwriting discount, including 150,000 Class A ordinary shares, which we refer to herein as the “representative shares.” See also “Underwriting” for a description of compensation and other items of value payable to the underwriters. |

Of the proceeds we receive from this offering
and the sale of the private placement units described in this prospectus, $150,000,000, or $172,500,000 if the underwriters’
overallotment option is exercised in full ($10.00 per unit in either case), will be placed into a U.S.-based trust account with Continental
Stock Transfer & Trust Company acting as trustee.

Because our sponsor acquired the founder shares at a nominal price, our public shareholders will incur an immediate and material dilution upon the closing of this offering. Further, the Class A ordinary shares issuable in connection with the conversion of the founder shares may result in material dilution to our public shareholders due to the anti-dilution rights of